RxDoctor Payments Data

Sripriya Srinivasan, MD

Psychiatry · Woonsocket, RINPI 1376729061

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $373 of the $462 with a category attached, or 80.6%. 9 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 32.6% of the total.

$462in general payments, 2019–2025

Across 16 payments — averaging $28.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$151
  • Otsuka America Pharmaceutical, Inc.$77
  • Neurocrine Biosciences, Inc.$51
  • Indivior Inc.$44
  • Vanda Pharmaceuticals Inc.$38
  • Alkermes, Inc.$35
  • plus $66 from 3 others

What the payments were for

  • Food & beverage$37381%
  • Education$8919%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$462 in reported general payments places this provider in the 75th percentile of 209 psychiatry providers in Rhode Island.

See all psychiatry providers in Rhode Island

Medicare billing

Part B allowed, 2024
$7,853
Medicare patients
18
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate15$113,194
Abilify MaintenaAripiprazole19$44,111
CaplytaLumateperone Tosylate11$17,108
Hydroxyzine Hcl223$5,208
Duloxetine Hcl91$4,211
Fluoxetine Hcl257$3,301
Quetiapine Fumarate186$3,182
Divalproex Sodium ErDivalproex Sodium19$2,218
Gabapentin85$1,878
Trazodone Hcl102$1,575
Naltrexone Hcl36$1,465
Quetiapine Fumarate ErQuetiapine Fumarate24$1,386
Venlafaxine Hcl ErVenlafaxine Hcl99$1,284
Sertraline Hcl135$1,270
Aripiprazole19$1,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza$18$113,19415 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$77$44,11119 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$34$17,10811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 209 psychiatry providers in Rhode Island.

Other psychiatry in Woonsocket

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →